JP5315253B2 - ラセミ型イラプラゾールの固体形 - Google Patents

ラセミ型イラプラゾールの固体形 Download PDF

Info

Publication number
JP5315253B2
JP5315253B2 JP2009544309A JP2009544309A JP5315253B2 JP 5315253 B2 JP5315253 B2 JP 5315253B2 JP 2009544309 A JP2009544309 A JP 2009544309A JP 2009544309 A JP2009544309 A JP 2009544309A JP 5315253 B2 JP5315253 B2 JP 5315253B2
Authority
JP
Japan
Prior art keywords
ilaprazole
racemic ilaprazole
racemic
pharmaceutical composition
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009544309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514806A5 (enExample
JP2010514806A (ja
Inventor
ジョン エム． ブラケット
デービット ティー． ジョナイティス
ウェイ ライ
ジン ハ リウ
ステファン ディー． パレント
ジンユ シェン
Original Assignee
イル ヤン ファーマスーティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イル ヤン ファーマスーティカル カンパニー リミテッド filed Critical イル ヤン ファーマスーティカル カンパニー リミテッド
Publication of JP2010514806A publication Critical patent/JP2010514806A/ja
Publication of JP2010514806A5 publication Critical patent/JP2010514806A5/ja
Application granted granted Critical
Publication of JP5315253B2 publication Critical patent/JP5315253B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2009544309A 2006-12-29 2007-12-28 ラセミ型イラプラゾールの固体形 Active JP5315253B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US60/877,608 2006-12-29
US88749907P 2007-01-31 2007-01-31
US60/887,499 2007-01-31
PCT/US2007/089127 WO2008083333A1 (en) 2006-12-29 2007-12-28 Solid state forms of racemic ilaprazole

Publications (3)

Publication Number Publication Date
JP2010514806A JP2010514806A (ja) 2010-05-06
JP2010514806A5 JP2010514806A5 (enExample) 2011-02-24
JP5315253B2 true JP5315253B2 (ja) 2013-10-16

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009544309A Active JP5315253B2 (ja) 2006-12-29 2007-12-28 ラセミ型イラプラゾールの固体形
JP2009544310A Expired - Fee Related JP5315254B2 (ja) 2006-12-29 2007-12-28 溶媒和物化されたイラプラゾールの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009544310A Expired - Fee Related JP5315254B2 (ja) 2006-12-29 2007-12-28 溶媒和物化されたイラプラゾールの結晶形

Country Status (18)

Country Link
US (4) US7999110B2 (enExample)
EP (2) EP2102192B1 (enExample)
JP (2) JP5315253B2 (enExample)
KR (3) KR20110091594A (enExample)
CN (2) CN101687849B (enExample)
AU (2) AU2007341984B2 (enExample)
CA (2) CA2674358C (enExample)
DK (1) DK2102192T3 (enExample)
ES (1) ES2398846T3 (enExample)
IL (2) IL199242A (enExample)
MX (2) MX2009006529A (enExample)
MY (2) MY145936A (enExample)
NO (2) NO20092398L (enExample)
NZ (2) NZ577509A (enExample)
PL (1) PL2102192T3 (enExample)
PT (1) PT2102192E (enExample)
RU (2) RU2464270C2 (enExample)
WO (2) WO2008083341A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (ko) * 2009-12-08 2012-05-16 일양약품주식회사 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
WO2013114232A1 (en) * 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746277B (zh) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN103172618B (zh) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 艾普拉唑晶型及其制备方法
CN104370886B (zh) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 艾普拉唑晶型及其制备方法和应用
CN105055342A (zh) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂
CN105055343A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂
CN106749191A (zh) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 艾普拉唑晶型ⅱ及其制备方法
KR101961028B1 (ko) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물
KR102332996B1 (ko) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법
CN117050060A (zh) * 2023-07-20 2023-11-14 浙江美诺华药物化学有限公司 一种艾普拉唑晶型f的制备方法
KR20250156870A (ko) 2024-04-25 2025-11-04 엠에프씨 주식회사 일라프라졸 마그네슘염 수화물의 제조방법
CN119462610A (zh) * 2024-11-06 2025-02-18 甘肃皓天科技股份有限公司 一种艾普拉唑新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (ru) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2003224779A1 (en) 2002-03-27 2003-10-13 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
ES2375298T3 (es) 2005-03-25 2012-02-28 Livzon Pharmaceutical Group Inc. Procedimiento para preparar derivados de sulfóxido sustituidos.
WO2006118534A1 (en) * 2005-05-04 2006-11-09 Astrazeneca Ab Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux

Also Published As

Publication number Publication date
US20110046184A1 (en) 2011-02-24
EP2102191B1 (en) 2012-11-21
HK1140483A1 (en) 2010-10-15
DK2102192T3 (da) 2013-03-04
MY146462A (en) 2012-08-15
US7989632B2 (en) 2011-08-02
CA2674358C (en) 2013-10-08
AU2007341992B2 (en) 2012-07-05
US7999110B2 (en) 2011-08-16
NO20092398L (no) 2009-09-28
CN101687849B (zh) 2013-05-29
EP2102192A1 (en) 2009-09-23
NZ577509A (en) 2012-01-12
CN101687849A (zh) 2010-03-31
US20110082174A1 (en) 2011-04-07
EP2102191A1 (en) 2009-09-23
MX2009006530A (es) 2009-08-18
WO2008083341A1 (en) 2008-07-10
WO2008083333A1 (en) 2008-07-10
IL199242A (en) 2013-10-31
CA2674347A1 (en) 2008-07-10
JP2010514806A (ja) 2010-05-06
US8592600B2 (en) 2013-11-26
AU2007341984B2 (en) 2012-07-05
HK1140484A1 (en) 2010-10-15
CN101687848B (zh) 2013-05-15
CA2674358A1 (en) 2008-07-10
RU2466129C2 (ru) 2012-11-10
CN101687848A (zh) 2010-03-31
RU2009122242A (ru) 2011-02-10
KR20090086121A (ko) 2009-08-10
AU2007341992A1 (en) 2008-07-10
MY145936A (en) 2012-05-31
RU2464270C2 (ru) 2012-10-20
KR20110091594A (ko) 2011-08-11
US20080200517A1 (en) 2008-08-21
KR20090086615A (ko) 2009-08-13
JP2010514807A (ja) 2010-05-06
JP5315254B2 (ja) 2013-10-16
PL2102192T3 (pl) 2013-04-30
NZ577129A (en) 2012-02-24
ES2398846T3 (es) 2013-03-22
NO20092464L (no) 2009-09-28
RU2009122241A (ru) 2011-02-10
US8592599B2 (en) 2013-11-26
MX2009006529A (es) 2009-08-18
IL199234A (en) 2013-07-31
CA2674347C (en) 2013-08-06
US20080200516A1 (en) 2008-08-21
KR101052387B1 (ko) 2011-07-28
EP2102192B1 (en) 2012-11-14
AU2007341984A1 (en) 2008-07-10
PT2102192E (pt) 2013-01-23
NO342530B1 (no) 2018-06-11

Similar Documents

Publication Publication Date Title
JP5315253B2 (ja) ラセミ型イラプラゾールの固体形
US9957240B2 (en) Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
US20080200515A1 (en) Solid state forms of enantiopure ilaprazole
JP2023550428A (ja) インテグリン阻害剤およびその使用
EP3524240A1 (en) Urea derivative
US20250197393A1 (en) Integrin inhibitor and uses thereof
JP5181675B2 (ja) ジヒドロピリジン誘導体の酸付加塩
HK1140484B (en) Solid state forms of racemic ilaprazole
BRPI0719624A2 (pt) Formas de estado sólido do ilaprazol racêmico
KR20250164238A (ko) 벤즈이미다졸 유도체의 염
BRPI0719624B1 (pt) Formas de estado sólido do ilaprazol racêmico
JP2008290989A (ja) ジヒドロピリジン誘導体の酸付加塩を含有する医薬
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物
HK1140483B (en) Crystalline forms of solvated ilaprazole

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130708

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5315253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250